This trial is evaluating whether walnuts will improve 1 primary outcome and 2 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of 10 weeks.
This trial requires 50 total participants across 2 different treatment groups
This trial involves 2 different treatments. Walnuts is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
Men with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) have increased circulating testosterone levels, increased free prostate-specific antigen or elevated prostate-specific antigen/total prostate-specific antigen ratio. These are the only findings on physical examination suggestive of prostate cancer. We recommend that a biopsy be performed in such men. However, we have found no other findings which would exclude a diagnosis of prostate cancer. There is no evidence for increased serum prostate-specific antigen in any other condition. If serum prostate-specific antigen is elevated then further measurements may be useful in excluding prostate cancer.
The major risks factor for prostate cancer are: advancing age; high grade Gleason score; high PSA; family history of prostate cancer; and a personal history of prostate cancer.
Prostate cancer (PCa) is a devastating disease that typically appears in older men, especially those over the age of 50. It is a disease that forms in the lining of the prostate and can occur at any time in an individual's life. However, PCa is not the main cause of morbidity and mortality in older men; the primary causes are cardiovascular diseases and chronic and degenerative conditions of the genitourinary tract. PCa has a very poor prognosis, even with surgical treatment. Patients with PCa have a high risk of developing life-threatening complications, including bleeding and heart attacks.
We summarize the most commonly used treatments for [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) and include the patient's overall health and the severity of each cancer's treatment requirements into the picture.
The most recent estimate indicates that 5,600 to 10,000 men in the U.S. were diagnosed with prostate cancer during 1999. Based on these estimates, about 1.7 million men were diagnosed with prostate cancer during 1999. Among men and survivors, prostate cancer prevalence declined by 29 percent between 1979 and 2003.
In the absence of alternative treatments, early detection and aggressive management in the asymptomatic setting are the best forms of prevention, and they may reduce metastatic spread to distant sites.
Walnuts are the second most common herbal supplement used to treat prostate cancer after soy, based on a cross-sectional design review. The current literature suggests that walnuts are safe and may be effective for prostate cancer. Further investigation is necessary to assess the effect of walnuts in people with existing prostate cancer. Current results of prospective studies are awaited. Current evidence suggests that walnuts have a role in managing prostate cancer, because it lowers PSA and slows the progression of prostate cancer.
In light of the limitations of the reviews, we conclude that there is a lot of promise in [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) research. In particular, the area of prostate specific antigen testing has seen some breakthrough research. It remains challenging however to determine whether the findings will translate into an altered paradigm in prostate cancer management.
Ingestion of walnuts is an important preventive strategy against prostate cancer. In a recent study, findings provide insight into the molecular basis of this protection and highlight the importance of developing prostate cancer prevention strategies, particularly considering the increasing incidence of prostatitis caused by probiotic bacteria, as many of our patients are being provided with probiotic-containing probiotics, either for or against treatment of prostate cancer.
The current data do not support the use of walnut oil (150 or 300 g/day) in the treatment of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer). Whether walnut oil has any pharmacological role in treating prostate disease requires further investigation.
Walnut products may have potential for use in prostate disease and are worthy of further investigation. We discuss the rationale for these investigations by comparing the various properties of walnut components and walnut preparations with their potential anti-prostatic effects.
The odds of developing [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) in men who had prostate biopsy depend on the level of PSA, age, race, ethnicity, and family history. Men with a family history of prostate cancer in their first-degree male relatives have a 5x greater incidence of developing prostate cancer at a later age and a 10x greater incidence after the age of 70.